Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters

Genes Chromosomes and Cancer

Volumn 49, Issue 9, 2010, Pages 851-859

  Haferlach, Claudia ^a   Dicker, Frank ^a   Weiss, Tamara ^a   Schnittger, Susanne ^a   Beck, Christian ^b   Grote Metke, Albert ^c   Oruzio, Daniel ^d   Kern, Wolfgang ^a   Haferlach, Torsten ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b MVZ Onkologie Mönchengladbach   (Germany)

^c Gemeinschaftspraxis für Hämatologie und Internistische Onkologie   (Germany)

^d KLINIKUM AUGSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CYTOTOXIC AGENT; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN P53; ATM PROTEIN, HUMAN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; IMMUNOGLOBULIN VARIABLE REGION; PROTEIN SERINE THREONINE KINASE; TP53 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 14Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME BANDING ANALYSIS; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; HUMAN; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TREATMENT OUTCOME; CHROMOSOME BANDING PATTERN; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; DNA-BINDING PROTEINS; FEMALE; GENE DELETION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; ATAXIA TELANGIECTASIA MUTATED PROTEINS;

EID: 77955485242     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20794     Document Type: Article

References (35)

1. Best OG, Gardiner AC, Davis ZA, Tracy I, Ibbotson RE, Majid A, Dyer MJ, Oscier DG. 2009. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia 23:212-214.
2. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA. 2006. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 24:437-443.
3. Cavazzini F, Hernandez JA, Gozzetti A, Russo RA, de Angeli C, Tiseo R, Bardi A, Tammiso E, Crupi R, Lenoci MP, Forconi F, Lauria F, Marasca R, Maffei R, Torelli G, Gonzalez M, Martin-Jimenez P, Maria HJ, Rigolin GM, Cuneo A. 2008. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. Br J Haematol 142:529-537.
4. Chun K, Hagemeijer A, Iqbal A, Slovak, ML. 2008. Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study. ASH Annu Meet Abstr 112:2681.
5. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. 1999. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847.
6. Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C. 2006. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 108:3152-3160.
7. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916. (Pubitemid 32064784)
8. Gahrton G, Robert KH, Friberg K, Zech L, Bird AG. 1980. Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B-cell-mitogen stimulation. Blood 56:640-647. (Pubitemid 10005668)
9. Gine E, Moreno C, Esteve J, Montserrat E. 2007. The role of stem-cell transplantation in chronic lymphocytic leukemia risk-dapted therapy. Best Pract Res Clin Haematol 20:529-543. (Pubitemid 47250496)
10. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC. 2007a. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25:799-804.
11. Grever MR, Lucas DM, Johnson AJ, Byrd JC. 2007b. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20:545-556. (Pubitemid 47250499)
12. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. 2007. Comprehensive genetic characterization of CLL: A study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 21:2442-2451.
13. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. 2008. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456.
14. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. 1999. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854. (Pubitemid 29430400)
15. Hauswirth AW, Jager U. 2008. Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia. Haematologica 93:14-19.
16. ISCN.1995. Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature. Mitelman F, editor. Basel, Switzerland: S. Karger.
17. ISCN.2005. An international System for Human Cytogenetic Nomenclature. Shaffer LG, Tommerup N, editors. Basel, Switzerland: S. Karger.
18. Juliusson G, Oscier DG, Fitchett M, Ross FM, Stockdill G, Mackie MJ, Parker AC, Castoldi GL, Guneo A, Knuutila S. 1990. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 323:720-724.
19. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. 2007. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 21:1885-1891.
20. Kern W, Dicker F, Schnittger S, Haferlach C, Haferlach T. 2009. Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia. Cytometry B Clin Cytom 76:385-393.
21. Kujawski L, Ouillette P, Erba H, Saddler C, Jakubowiak A, Kaminski M, Shedden K, Malek SN. 2008. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 112:1993-2003.
22. Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. 2008. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 113:3168-3171.
23. Matutes E, Owusu-Ankomah K, Morilla R, Garcia MJ, Houlihan A, Que TH, Catovsky D. 1994. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8:1640-1645.
24. Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. 2006. How I treat refractory CLL. Blood 107:1276-1283.
25. Nelson BP, Gupta R, Dewald GW, Paternoster SF, Rosen ST, Peterson LC. 2007. Chronic lymphocytic leukemia FISH panel: Impact on diagnosis. Am J Clin Pathol 128:323-332. (Pubitemid 47262633)
26. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, Corcoran MM, Chapman RM, Thomas PW, Copplestone JA, Orchard JA, Hamblin TJ. 2002. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100:1177-1184.
27. Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, Matutes E, Milligan D. 2004. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 125:294-317. (Pubitemid 38621761)
28. Put N, Konings P, Rack K, Jamar M, van Roy N, Libouton JM, Vannuffel P, Sartenaer D, Ameye G, Speleman F, Herens C, Poirel HA, Moreau Y, Hagemeijer A, Vandenberghe P, Michaux L. 2009. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin- 2 stimulation: A Belgian multicentric study. Genes Chromosomes Cancer 48:843-853.
29. Shanafelt TD, Geyer SM, Kay NE. 2004. Prognosis at diagnosis: Integrating molecular biologic insights into clinical practice for patients with CLL. Blood 103:1202-1210.
30. Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, Dewald GW. 2006. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 24:4634-4641.
31. Stilgenbauer S, Bullinger L, Lichter P, Dohner H. 2002. Genetics of chronic lymphocytic leukemia: Genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 16:993-1007. (Pubitemid 34618838)
32. Struski S, Gervais C, Helias C, Herbrecht R, Audhuy B, Mauvieux L. 2009. Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia 23:617-619.
33. Thorselius M, Krober A, Murray F, Thunberg U, Tobin G, Buhler A, Kienle D, Albesiano E, Maffei R, Dao-Ung LP, Wiley J, Vilpo J, Laurell A, Merup M, Roos G, Karlsson K, Chiorazzi N, Marasca R, Dohner H, Stilgenbauer S, Rosenquist R. 2006. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 107:2889-2894.
34. Tobin G, Thunberg U, Johnson A, Thorn I, Soderberg O, Hultdin M, Botling J, Enblad G, Sallstrom J, Sundstrom C, Roos G, Rosenquist R. 2002. Somatically mutated Ig V(H)3- 21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 99:2262-2264.
35. vanBockstaele F, Verhasselt B, Philippe J. 2009. Prognostic markers in chronic lymphocytic leukemia: A comprehensive review. Blood Rev 23:25-47.